242 related articles for article (PubMed ID: 24129240)
1. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
[TBL] [Abstract][Full Text] [Related]
2. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
[TBL] [Abstract][Full Text] [Related]
3. RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status.
Sonnemann J; Grauel D; Blümel L; Hentschel J; Marx C; Blumrich A; Focke K; Becker S; Wittig S; Schinkel S; Krämer OH; Beck JF
Eur J Cancer; 2015 May; 51(7):841-51. PubMed ID: 25801700
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.
Rökaeus N; Shen J; Eckhardt I; Bykov VJ; Wiman KG; Wilhelm MT
Oncogene; 2010 Dec; 29(49):6442-51. PubMed ID: 20818419
[TBL] [Abstract][Full Text] [Related]
5. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
[TBL] [Abstract][Full Text] [Related]
6. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1.
Hang W; Yin ZX; Liu G; Zeng Q; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Wang YS; Quan CS; Zhao RX; Li YL; Xu ZX
Oncogene; 2018 Jun; 37(25):3384-3398. PubMed ID: 29348462
[TBL] [Abstract][Full Text] [Related]
7. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Saha MN; Jiang H; Yang Y; Reece D; Chang H
Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
[TBL] [Abstract][Full Text] [Related]
8. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
[TBL] [Abstract][Full Text] [Related]
10. SLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than
Fujihara KM; Corrales Benitez M; Cabalag CS; Zhang BZ; Ko HS; Liu DS; Simpson KJ; Haupt Y; Lipton L; Haupt S; Phillips WA; Clemons NJ
Mol Cancer Ther; 2021 Oct; 20(10):1858-1867. PubMed ID: 34315763
[TBL] [Abstract][Full Text] [Related]
11. APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.
Liu DS; Read M; Cullinane C; Azar WJ; Fennell CM; Montgomery KG; Haupt S; Haupt Y; Wiman KG; Duong CP; Clemons NJ; Phillips WA
Gut; 2015 Oct; 64(10):1506-16. PubMed ID: 26187504
[TBL] [Abstract][Full Text] [Related]
12. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
13. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
15. APR-246 induces apoptosis and enhances chemo-sensitivity via activation of ROS and TAp73-Noxa signal in oesophageal squamous cell cancer with TP53 missense mutation.
Kobayashi T; Makino T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Morii E; Eguchi H; Doki Y
Br J Cancer; 2021 Nov; 125(11):1523-1532. PubMed ID: 34599296
[TBL] [Abstract][Full Text] [Related]
16. PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.
Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Strömblad S
Cell Cycle; 2011 Jan; 10(2):301-7. PubMed ID: 21239882
[TBL] [Abstract][Full Text] [Related]
17. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Deben C; Lardon F; Wouters A; Op de Beeck K; Van den Bossche J; Jacobs J; Van Der Steen N; Peeters M; Rolfo C; Deschoolmeester V; Pauwels P
Cancer Lett; 2016 Jun; 375(2):313-322. PubMed ID: 26975633
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome profiling of Ewing sarcomas - treatment resistance pathways and IGF-dependency.
Chen Y; Hesla AC; Lin Y; Ghaderi M; Liu M; Yang C; Zhang Y; Tsagkozis P; Larsson O; Haglund F
Mol Oncol; 2020 May; 14(5):1101-1117. PubMed ID: 32115849
[TBL] [Abstract][Full Text] [Related]
19. RNA sequencing and functional studies of patient-derived cells reveal that neurexin-1 and regulators of this pathway are associated with poor outcomes in Ewing sarcoma.
Roundhill EA; Chicon-Bosch M; Jeys L; Parry M; Rankin KS; Droop A; Burchill SA
Cell Oncol (Dordr); 2021 Oct; 44(5):1065-1085. PubMed ID: 34403115
[TBL] [Abstract][Full Text] [Related]
20. Prima-1 and APR-246 in Cancer Therapy.
Zatloukalová P; Galoczová M; Vojtěšek B
Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
